That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...
AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...
Designation underscores the potential of this chemically induced, off-the-shelf cell therapy to address a high unmet need in ...
Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...
Hopes were high Wednesday for a billion-dollar megadeal—the kind the J.P. Morgan Healthcare Conference is known for—but no ...
It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. | It’s been a subdued—albeit ...
Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...
Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...
Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...
Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...
The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...
Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback